March 16 (Reuters) - Sarepta Therapeutics Inc SRPT.O:
SAREPTA ANNOUNCES THAT SCREENING AND ENROLLMENT ARE UNDERWAY IN ENDEAVOR COHORT 8 TO EVALUATE ENHANCED IMMUNOSUPPRESSION REGIMEN AS PART OF ELEVIDYS GENE THERAPY FOR NON-AMBULANT INDIVIDUALS WITH DUCHENNE